Test Overview
Test Methodology

Multiplex Flow Immunoassay

Test Usage

Support diagnosis of EBV infection.

Reference Range *

NEGATIVE: Indicates no detectable IgG antibody to EBV Early Antigen; EQUIVOCAL: Presence or absence of IgG antibody to EBV Early Antigen cannot be determined. Another specimen should be sent for analysis; POSITIVE: Indicates detectable levels of IgG antibody to EBV Early Antigen.

* Reference ranges may change over time. Please refer to the original patient report when evaluating results.

Test Limitations

Assay performance characteristics have not been established for immunocompromised or immunosuppressed patients, cord blood, neonatal specimens or infants. Assay performance characteristics have not been established for the diagnosis of nasopharyngeal carcinoma, Burkitt’s lymphoma and other EBV-associated lymphomas.

Test Details
Days Set Up
Monday - Friday
Analytic Time

24 hours

Soft Order Code
EBVEA
MiChart Code
Epstein-Barr virus early antigen antibody, IgG
Synonyms
  • EBVEAG
  • EBV Early Antigen, IgG
  • EBVEA
Laboratory
Chemical Pathology
Section
Immunopathology
Specimen Requirements
Collection Instructions

Collect specimen in SST tube.
Centrifuge, aliquot serum into a plastic vial and refrigerate.

Alternate Specimen
Red top tube.
Normal Volume
0.5 mL serum
Minimum Volume
0.25 mL serum
Rejection Criteria
CSF is not acceptable.
Additional Information

IgG antibodies to EA-D are frequently present in acute IM and generally absent in convalescence. A rise may indicate acute infection, reactivation or chronic infection. The presence of antibodies in other healthy individuals usually indicates reactivation, especially when paired with rising EBNA-1 levels. Antibody levels tend to rise and peak after 3-4 weeks, then decline and usually dissipate after 6 months.

Billing
CPT Code
86663
Fee Code
36600
LOINC
40752-8